Drugs / ESL
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01820559 Comparator | Apr 2009 → Jun 2010 | migraine disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01820559 ↗ |
| Route | Oral | “administered with a dose of 800 or 1200 mg QD in the evening by the oral route.” NCT01820559 ↗ |